Investasi
Fitur
BiayaKeamanan
Akademi
Lainnya
Pluang+

Bandingkan Harga & Kinerja Organon Pharma Indonesia Tbk. (SCPI) vs Reksa Dana Indeks Simas ETF IDX30 (XSBC)

Organon Pharma Indonesia Tbk.Trading
Reksa Dana Indeks Simas ETF IDX30Trading

Kinerja harga (24 Jam Terakhir)

Statistik utama

Perbedaan Organon Pharma Indonesia Tbk. dan Reksa Dana Indeks Simas ETF IDX30: Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M), sedangkan Reksa Dana Indeks Simas ETF IDX30 diperdagangkan di Rp96 (kapitalisasi pasar 12,06 M). Perbedaan utamanya: Organon Pharma Indonesia Tbk. jauh lebih besar — sekitar 8,7× kapitalisasi pasar Reksa Dana Indeks Simas ETF IDX30. Mana yang lebih baik tergantung tujuan investasimu.

SCPIXSBC
Kapitalisasi Pasar
104,4 M12,06 M

Perbandingan imbal hasil

Imbal hasil berjalan pada periode standar

Berita terkini

Berita terbaru kedua aset

SCPI
Lihat detail

Tentang Organon Pharma Indonesia Tbk.

PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.

Selengkapnya di halaman SCPI

Tentang Reksa Dana Indeks Simas ETF IDX30

Selengkapnya di halaman XSBC